Drug industry antitrust act : hearings before the Antitrust Subcommittee (Subcommittee No. 5) of the Committee on the Judiciary, House of Representatives, Eighty-seventh Congress, second session, on H.R. 6245, a bill to amend and supplement the antitrust laws with respect to the manufacture and distribution of drugs and for other purposes, May 17, 18, 23, and 24, 1962

Drug industry antitrust act : hearings before the Antitrust Subcommittee (Subcommittee No. 5) of the Committee on the Judiciary, House of Representatives, Eighty-seventh Congress, second session, on H.R. 6245, a bill to amend and supplement the antitrust laws with respect to the manufacture and distribution of drugs and for other purposes, May 17, 18, 23, and 24, 1962.

Author/creator	United States. Congress. House. Committee on the Judiciary. Subcommittee No. 5.
Format	Book and Print
Publication Info	Washington : U.S. Govt. Print. Off, 1962.
Description	vii, 908 pages : illustrations ; 24 cm
Subject(s)	United States. Food and Drug Administration. Drugs--Law and legislation --United States. Antitrust law--United States. Pharmaceutical policy--United States. Pharmaceutical industry--Standards --United States.

Abstract	Committee Serial No. 32. Considers legislation to eliminate anticompetitive practices in the patenting, licensing, and marketing of drugs, and to require FDA standardization of drug names and stricter safety and efficacy standards for new drugs.
General note	Emanuel Celler, subcommittee chairman.
Other forms	Available also in microform in CIS US congressional committee hearings, accession number (87)H1952-1.
LCCN	62062353
Govt. docs number	Y 4.J 89/1:87/32

Library	Location	Call Number	Status	Item Actions
Joyner	Fed Docs Stacks	Y 4.J 89/1:87/32	✔ Available	Place Hold